Dec 05, 2023 Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
Nov 13, 2023 Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Oct 18, 2023 Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
Oct 02, 2023 Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
Sep 06, 2023 Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Aug 14, 2023 Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Jul 31, 2023 Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
Jul 27, 2023 Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results Demonstrating Substantial Increases in Complete Response Rates in Advanced Cutaneous Squamous Cell Carcinoma
Jun 28, 2023 Checkpoint Therapeutics Announces Presentation of New Cosibelimab Pharmacokinetic Data Supporting Extended-Interval Dosing